Our Approach
JDRF is focused on developing drugs that change the course of T1D from everyone affected by it—and those yet to be. That means slowing or halting the progression of the disease, preventing it from ever occurring, and reversing it entirely.
Program Goals
Stop the immune system from attacking healthy beta cells, preventing T1D from ever occurring.
Spur beta cell growth safely and protect them, so people with T1D can live without life-long external insulin.
Develop treatments that can halt, slow or reverse the events that drive T1D.
Progress
Looking ahead
In the past decade, JDRF has invested more than $345 million in disease-modifying therapies, and there are several in human clinical trials. One therapy has even been submitted for approval and is awaiting a ruling from the U.S. Food and Drug Administration.
Want to learn more? View JDRF scientists below for a presentation on JDRF’s efforts in disease-modifying therapies here.
Screening
Developing a global universal T1D risk screening strategy to identify high-risk individuals, reduce DKA at diagnosis, and speed up the development of disease-modifying therapies by accelerating clinical trials.
Cell Therapies
Investing in research and clinical trials aimed at developing and delivering life-changing therapies that insert healthy, insulin-producing beta cells into people with T1D, with minimal or no immunosuppression, keeping them healthy for longer.
Improving Lives
People with T1D must have tools, therapies, and interventions to keep them healthy so that when cures come to fruition, they are healthy enough to take advantage of them.